Cell Therapeutics' Dual Strategy On Pixuvri Will Be Tested At Advisory Committee
This article was originally published in The Pink Sheet Daily
Executive Summary
While appealing the “complete response” letter it got for its non-Hodgkin’s lymphoma treatment Pixuvri on the basis of re-analyzed data, Cell Therapeutics also is doing the additional combination trial the agency requested.